Lima
+918770708752

Regonat 40mg Tablet Specifications for Pharmacies in Lima

A pharmacy cannot approve a Regonat quotation from the brand name and strength alone: the presentation, registration pathway, batch records, storage history and remaining shelf life all affect whether stock is dispensable in Peru. By the end, you will have a specification, receiving checklist and procurement test for comparing regorafenib offers in Lima.

Key takeaways

  • Confirm regorafenib 40 mg strength, authorised presentation and tablet description.
  • Request the DIGEMID registration details and approved Spanish technical sheet.
  • Check storage conditions, batch number, expiry date and seal at receipt.
  • Reject offers with mismatched packs, missing documents or inadequate remaining shelf life.

What exact Regonat 40 mg presentation should a Lima pharmacy order?

Order only after the supplier identifies the product as regorafenib 40 mg per film-coated tablet for oral administration. The quotation must reproduce the registered product name, manufacturer, authorised presentation and the tablet description in the approved Spanish technical sheet, including colour, shape, coating and any imprint.

A brand name alone is insufficient for regonat 40mg tablet for specifications in lima.

1. Ask the supplier to state whether the tablets arrive in a moisture-protective bottle with desiccant or in blisters. Do not apply bottle instructions to blister stock. Request the tablet count per carton, units per bottle or blister, pack configuration, and whether partial cartons or partial batches are available.

2. Treat 40 mg as the strength of one tablet, not the patient’s prescribed daily dose. The labelled 160 mg daily schedule equals four tablets on days 1–21 of a 28-day cycle; a 120 mg reduction requires three tablets, and 80 mg requires two.

Treatment interruptions and the seven-day break affect replenishment forecasts, so buying four tablets for every calendar day can overstate demand.

3. Dispense according to the prescription and approved local label, never a buyer’s calculation. Before accepting a quotation, obtain the lot number, manufacture date, expiry date and remaining shelf life, together with the approved Spanish technical sheet and sanitary-registration details.

Which approved uses and administration instructions must accompany the stock?

Verify the approved Spanish technical sheet before dispensing: the indication must name the disease, prior treatment and eligible patient population, not merely “advanced cancer.”

IndicationRequired prior treatment and populationPharmacy verification
Metastatic colorectal cancerFluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, plus an anti-VEGF and, when appropriate, anti-EGFR therapyConfirm identical wording in the Peruvian-approved label
Unresectable or metastatic gastrointestinal stromal tumourPrior imatinib and sunitinibConfirm the tumour status and treatment history are covered
Hepatocellular carcinomaPrevious treatment with sorafenibConfirm the Peruvian label includes this population

The product information must state that tablets are taken after a low-fat meal: less than 30% fat and approximately 600 calories or less. Swallow each tablet whole with water unless the local approved label says otherwise.

For searches such as regorafenib tablets peru, do not turn a missed dose into a new schedule; use the approved label or prescriber’s instruction.

The oncology prescriber makes treatment decisions. The dispensing pharmacist must screen strong CYP3A4 inhibitors, including clarithromycin, ketoconazole and grapefruit products, and inducers such as rifampin.

The dispensing file should flag these continuity controls:

  • Liver-function testing before treatment, every two weeks during the first two months, then at least monthly.
  • Blood-pressure measurement before treatment and weekly for six weeks, then periodic monitoring.
  • Hepatotoxicity, hypertension, hand-foot skin reaction, haemorrhage and impaired wound healing as risks requiring clinical follow-up.

How should Regonat tablets be stored and received in Lima?

Keep delivered Regonat stock in quarantine until its storage history, packaging and identifiers support release. The Regonat tablet storage conditions are 25 °C, with permitted excursions from 15 °C to 30 °C, in the original container and protected from moisture.

1. For bottle-packed tablets, keep the bottle tightly closed and retain its desiccant. For blister-packed Regonat, obtain the manufacturer’s validated moisture-protection and shelf-life instructions; do not transfer bottle directions to blister stock.

2. Record the labelled shelf-life, expiry-date format and minimum remaining shelf life agreed in the purchase order. Do not dispense expired stock or relabel an unclear date.

3. At receipt, photograph and inspect the tamper-evident seal, outer carton, blister foil or bottle, desiccant, tablet colour and shape, batch or lot number, manufacture date, expiry date, Spanish import label and quantity.

4. Reconcile every identifier against the invoice, packing list and certificate of analysis. Quarantine the shipment after a temperature excursion, wet or damaged carton, broken seal, missing lot number or quantity mismatch.

5. Request the transport-temperature record and a written quality decision from the manufacturer or authorised quality unit before release. A generic “store at room temperature” statement does not establish suitability after transport.

Release only when the documents match the physical stock and the agreed shelf-life remains acceptable. A damaged pack or unexplained excursion requires documented investigation, not a visual assumption that the tablets remain usable.

How can a Lima buyer verify authorisation and compare supplier offers?

Before accepting an overseas quotation, confirm that the exact Regonat 40 mg presentation is authorised for Peruvian supply. In the DIGEMID sanitary-registration system, match the brand, regorafenib 40 mg strength, film-coated tablet form, pack size, manufacturer, registration holder and proposed importer.

A foreign export listing or certificate of analysis alone does not prove permission to sell in Peru. Apply the same test to a regonat 40 mg supplier in Lima or a regonat 40mg pharmaceutical supplier. NIBA HEALTHCARE should be assessed on these records, not on its name.

Request the following before procurement:

  • Commercial invoice, packing list, batch certificate of analysis, certificate of pharmaceutical product or equivalent registration evidence, and certificate of origin.
  • Transport-temperature conditions, chain-of-custody records, lot traceability, expiry at delivery and Spanish-language labelling where required.
  • The Peruvian pharmacovigilance and product-complaint contact, including the person responsible for recalls.
  • Import authorisation when the route is an import or compassionate-use pathway rather than a registered commercial presentation.
CheckRegistered commercial offerImport or compassionate-use offer
AuthorisationDIGEMID registration matches presentationSpecific import authorisation before purchase
Comparison basisManufacturer, pack count and registration holderSame fields plus route restrictions
Landed costProduct, freight, insurance, customs or brokerage, taxes or duties, Lima deliveryAdd temperature-control, quarantine and replacement-stock costs
Supply reliabilityLead time, minimum order, replenishment and partial batchesConfirm each condition in writing

Related product

REGONAT

Regorafenib Tablets 40 Mg

REGONAT

Tablet should be taken with food, but try to have it at the same time every day to get the most benefits.

When does a Regonat order fit the pharmacy’s operation, and when should it be rejected?

After technical and regulatory checks pass, accept the order only if the receiving channel can support safe dispensing, monitoring, traceability and timely treatment supply.

  1. A hospital or oncology clinic should match the quantity to named patients and valid prescriptions. Confirm laboratory monitoring, blood-pressure checks, secure oncology-pharmacy handling and a documented contact for complaints or recalls before release.
  2. A retail pharmacy should confirm that it is authorised to dispense this prescription antineoplastic medicine. The pharmacist must be available to refer questions about interactions, adverse effects, treatment interruptions and dose changes to the prescriber.
  3. A distributor should record the minimum order quantity, replenishment lead time, emergency-order process, partial-batch policy, minimum expiry threshold and notification timing for complaints or recalls.

Pause or reject the order when:

  • The proposed brand, strength, dosage form or pack differs from the Peruvian registered presentation.
  • Batch documents, lot numbers or certificates of analysis cannot be verified.
  • Remaining shelf life is too short for the planned dispensing channel.
  • Delivery will miss the patient’s required treatment supply date.
  • The pharmacy cannot maintain the labelled storage conditions.
  • The comparison uses a 40 mg tablet price without stating pack count.
  • The offer confuses regorafenib with another oncology tablet or brand.
  • An export listing is treated as proof of Peruvian market authorisation.

Procurement cannot replace clinical review. The prescriber and pharmacist must manage regimen changes, liver-function and blood-pressure monitoring, adverse reactions and interaction screening.

Frequently asked questions

  • What exact Regonat 40 mg presentation should a Lima pharmacy order?

    Order only when the quotation identifies Regonat as regorafenib 40 mg per film-coated tablet for oral administration and matches the authorised product name, manufacturer, pack presentation and tablet description in the approved Spanish technical sheet.

  • Which approved uses and administration instructions must accompany the stock?

    Request the approved Spanish technical sheet and package leaflet with the shipment. Use them to confirm the authorised indications, dose schedule, administration instructions, contraindications, interactions and monitoring requirements rather than relying on a supplier summary.

  • How should Regonat tablets be stored and received in Lima?

    Follow the storage temperature, moisture and light instructions printed on the authorised label and technical sheet. At receipt, check the outer seal, batch number, expiry date, pack integrity and transport records, then quarantine discrepancies.

  • How can a Lima buyer verify authorisation and compare supplier offers?

    Ask for the DIGEMID registration details, manufacturer identity, authorised presentation, technical sheet and traceability documents. Compare offers on the same strength, pack size, remaining shelf life, delivery conditions and documentation—not price alone.

  • When does a Regonat order fit the pharmacy’s operation, and when should it be rejected?

    Proceed only when the pharmacy can lawfully procure, store, document and dispense a prescription oncology medicine and the supplier provides matching authorised stock. Reject an offer with an unverified registration, mismatched presentation, damaged seal, missing batch details or unsuitable storage history.

 2026-09-30T09:00:19

Keywords